Announcements Trials
Browse Landscape

Phase

Phase 1 3

Status

Completed 3

Sponsor Class

OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

Genitourinary 3

Conditions

Prostatic Neoplasms 3

Interventions

Docetaxel 292Prednisone 241enzalutamide 195Leuprolide 185Radiotherapy 179Abiraterone Acetate 170Magnetic Resonance Spectroscopy 163bicalutamide 141Goserelin 138Androgen Antagonists 121acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 108Radiosurgery 108apalutamide 93abiraterone 83gallium 68 PSMA-11 81Specimen Handling 73darolutamide 67Surveys and Questionnaires 64Gonadotropin-Releasing Hormone 63Triptorelin Pamoate 58Radiation 57Biopsy 57Brachytherapy 54cabazitaxel 53Standard of Care 51Radiotherapy, Intensity-Modulated 51Zoledronic Acid 50pembrolizumab 49luprolide acetate gel depot 49Flutamide 47

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Prostatic Neoplasms × saponin QA-21V1 × Genitourinary × Clear all
NCT00036933 2013-03-25

Vaccine Therapy Plus QS21 in Treating Patients With Prostate Cancer

Memorial Sloan Kettering Cancer Center

Phase 1 Completed
9 enrolled
Genitourinary

Prostatic Neoplasms

NCT00003819 2013-03-19

Vaccine Therapy Plus QS21 in Treating Patients With Progressive Prostate Cancer

Memorial Sloan Kettering Cancer Center

Phase 1 Completed
21 enrolled
Genitourinary

Prostatic Neoplasms

NCT00004929 2013-01-31

Vaccine Therapy Plus QS21 in Treating Patients With Progressive Prostate Cancer

Memorial Sloan Kettering Cancer Center

Phase 1 Completed
15 enrolled
Genitourinary

Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡